Arvinas (NASDAQ:ARVN) Reaches New 12-Month Low – Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN) hit a new 52-week low on Monday . The stock traded as low as $16.43 and last traded at $16.26, with a volume of 210125 shares. The stock had previously closed at $17.77.

Wall Street Analyst Weigh In

ARVN has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $87.00 price target on shares of Arvinas in a research note on Wednesday, December 11th. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 price objective (down previously from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Barclays dropped their price objective on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Stephens assumed coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective on the stock. Finally, BTIG Research assumed coverage on Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective for the company. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, Arvinas presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Arvinas Trading Down 4.7 %

The stock’s fifty day simple moving average is $18.49 and its 200 day simple moving average is $22.91. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -6.11 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the firm earned ($2.53) earnings per share. On average, analysts predict that Arvinas, Inc. will post -3.81 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ARVN. T. Rowe Price Investment Management Inc. purchased a new position in Arvinas in the fourth quarter valued at $42,332,000. Norges Bank acquired a new stake in Arvinas during the 4th quarter worth $23,845,000. Boxer Capital Management LLC acquired a new stake in shares of Arvinas in the 4th quarter valued at about $20,294,000. Braidwell LP increased its holdings in shares of Arvinas by 148.3% in the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after acquiring an additional 767,242 shares during the period. Finally, RTW Investments LP lifted its position in Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock worth $63,919,000 after acquiring an additional 551,979 shares during the period. 95.19% of the stock is currently owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.